Qyuns <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Industrialization Base Passes EU QP Audit Meeting EU GMP Standards
Qyuns Therapeutics Co. Ltd. has announced that its subsidiary, Jiangsu Cellularforce Biopharma Co., Ltd., has successfully passed the EU Qualified Person (QP) audit and received the official compliance audit report. This achievement confirms that the company's industrialization base meets EU Good Manufacturing Practice (GMP) standards for pharmaceuticals. The audit, conducted by a senior QP in accordance with EudraLex Volume 4 and related guidelines, recognized Cellularforce's high-standard quality management system, advanced facilities, and professional capabilities. This milestone supports the company's efforts in providing globally compliant biologics CDMO services. No grant or funding involving multiple organizations was mentioned in the announcement.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Qyuns Therapeutics Co. Ltd. published the original content used to generate this news brief on October 10, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。